Cabaletta Bio, Inc. (CABA)

Market Cap	595.25M
Revenue (ttm)	n/a
Net Income (ttm)	-76.87M
Shares Out	48.28M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700,770
Open	12.68
Previous Close	12.62
Day's Range	12.25 - 12.83
52-Week Range	9.02 - 26.35
Beta	2.52
Analysts	Strong Buy
Price Target	33.88 (+174.33%)
Earnings Date	May 15, 2024

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: CABA

Analyst Forecast

According to 8 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $33.88, which is an increase of 174.33% from the latest price.

Price Target

$33.88

(174.33% upside)

Analyst Consensus: Strong Buy